Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2011-10-07 Director's Dealing
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2011-10-07 English
NONE
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company, NanoViricides, Inc., was unable to file its Form 10-K for the period ended June 30, 2011, on time and is requesting an extension. The document does not contain the actual 10-K report or financial data but is merely a notification about the delay in filing the 10-K. According to the MENU VS MEAL RULE, such a notification is an announcement related to a report, not the report itself. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories and includes officer certifications, attestations, and notifications like this one.
2011-09-28 English
FORM 4
Director's Dealing
2011-09-27 English
FORM 4
Director's Dealing
2011-09-22 English
NANOVIRCIDES INC 8-K 9-16-2011
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the extension of expiration dates for warrants and details about unregistered sales of equity securities. It does not contain comprehensive financial statements or detailed financial performance data. The document length is 4200 characters, which is relatively short and typical for an 8-K filing. The nature of the content is an update on financing activities (warrant extension and equity sales), which fits the Capital/Financing Update category. Therefore, the correct classification is Capital/Financing Update (CAP).
2011-09-22 English
FORM 4
Director's Dealing
2011-09-20 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.